SCHEMBL5137981

SCHEMBL5137981

O=C(c1cccnc1-c1ccc(C(F)(F)F)cc1)N(Cc1ccccc1)C1Cc2ccccc2C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OXTR P30559 1/20 0.43
AVPR1A P37288 1/20 0.43
MTTP P55157 2/20 0.39
APOB P04114 1/20 0.39
TRPV1 Q8NER1 6/20 0.39
CASR P41180 1/20 0.39
HCRTR1 O43613 2/20 0.38
HCRTR2 O43614 2/20 0.38
SMO Q99835 1/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2C8 P10632 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
CYP46A1 Q9Y6A2 1/20 0.37
PDK1 Q15118 2/20 0.37
HTR1A P08908 1/20 0.37
DRD2 P14416 1/20 0.37
HTR7 P34969 1/20 0.37
HTR6 P50406 1/20 0.37
MTOR P42345 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5134903 0.84 MTTP (0.50) MTTPAPOBHCRTR1HCRTR2
SCHEMBL5137351 0.74 DRD2 (0.40) CYP2C9CYP2C19DRD2
SCHEMBL5137387 0.73 MEN1 (0.57)
SCHEMBL5136194 0.73 AGER (0.43) HCRTR1HCRTR2
SCHEMBL29978735 0.72 TDP1 (0.61) TRPV1CYP3A4CYP2C9
SCHEMBL4197626 0.72 TDP1 (0.61) TRPV1CYP3A4CYP2C9
Hydrochloric Acid SCHEMBL6201867 0.71 KDM4E (0.59) TRPV1CYP3A4CYP2C9
SCHEMBL5359589 0.71 MEN1 (0.51)
SCHEMBL5136090 0.70 POLB (0.43) HCRTR1HCRTR2DRD2
SCHEMBL5138006 0.69 ALDH1A1 (0.50) HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed